slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,369
Current window 32,041-32,070
Pages 1,379
Rows per page 30
Component
32,041-32,070 of 41,369
38
The table highlights specific clinical improvements for six individual patients, emphasizing normalization of mobility.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
14
Includes a callout regarding COVID-19 impact on 2020 sales.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
24
The slide outlines the core assets (nemvaleukin alfa, IL-12, IL-18) and the strategic rationale for a spin-off.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
05
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
09
The slide uses a color-coded column layout to contrast fund performance against benchmarks, emphasizing historical outperformance.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
36
The chart uses a shaded region to denote the GFC period (roughly 2Q08 to 1Q09).Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
38
Includes a call-to-action button for an external document and a preview of a secondary slide.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
05
Includes B-Corp certification logo.AppHarvest | Results Presentation Deck | 13 slides · AppHarvest
Conference presentation Investor relations 1 hit
13
The slide displays 8 individual patient case studies (Pt 46, 51, 52, 53, 56, 58, 59, 60, 61).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
20
The slide uses a three-column layout to explain the scientific basis and benefits of the drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
Includes IC50 value and IFN-y fold increase data from patient samples.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The slide uses a three-column layout to highlight the core benefits of the product.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The slide maps the viral genome to specific drug targets and highlights partnerships with X-Chem and Proteros.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
26
The slide highlights key therapeutic advantages of the candidate drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
05
argenx SE | Investor Presentation Deck | 22 slidesargenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
06
The slide uses a hub-and-spoke style layout with a central mission statement and four surrounding strategic pillars.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
14
The slide uses a visual representation of an antibody structure to explain the 'sweeping' mechanism.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
16
The slide illustrates the neuromuscular junction mechanism and the clinical trial progression from healthy volunteers to patients with CMS and MuSK MG.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
18
The slide uses a network-like background with lines connecting various logos, suggesting a collaborative ecosystem.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
07
The slide highlights a total full-year revenue of $401M in the first year of launch.argenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations Beat · What Could BeLoop · Cost Of Inaction1 hit
08
Includes a callout for cash position at year-end.argenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations Beat · What Could BeLoop · Cost Of Inaction1 hit
11
The slide uses a circular cluster diagram to represent the four pillars surrounding the central 2025 goal.argenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations Beat · What Could BeLoop · Cost Of Inaction1 hit
14
Includes a map of Africa highlighting current and planned program countries.AstraZeneca | ESG Presentation Deck | 16 slides · AstraZeneca
Conference presentation Investor relations Beat · Future State1 hit
15
AstraZeneca | ESG Presentation Deck | 16 slidesAstraZeneca | ESG Presentation Deck | 16 slides · AstraZeneca
Conference presentation Investor relations Beat · Future State1 hit
04
Uses a hierarchical structure to break down the objective into three strategic pillars.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Solution1 hit
06
The slide uses a timeline framework to show past achievements and future milestones.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · RoadmapLoop · Why Now1 hit
09
Includes a quote from Keith Nuechterlein and specific Cohen's d effect size metrics.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Problem1 hit
11
The slide uses a dual-panel layout to compare animal model data (left) with human Phase 1 clinical trial data (right).ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
13
The slide uses a standard clinical trial flow diagram to illustrate the study protocol.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
16
The slide uses a line chart to show MADRS score changes over 12 weeks, highlighting the 25mg dose efficacy.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit